Genetic testing for BRCA1/2 gene variants for patients with metastatic castration-resistant prostate cancer

Two new MBS Item numbers for genetic testing

Page last updated: 31 March 2022

Effective 1 April 2022, patients with metastatic castration-resistant prostate cancer (mCRPC) will be able to access MBS funded genetic testing to detect both somatic and/or germline BRCA1 or BRCA2 gene variants, to determine eligibility for the Pharmaceutical Benefits Schedule (PBS) listed drug LynparzaŽ (olaparib).

PDF version Genetic testing for BRCA1/2 gene variants for patients with metastatic castration-resistant prostate cancer (PDF 151 KB)
Word version Genetic testing for BRCA1/2 gene variants for patients with metastatic castration-resistant prostate cancer (Word 89 KB)


In this section